Brief: Moleculin Miracle Trial Delivers 40% Preliminary Blinded CRc Rate (N=30)
18/02/2026 14:13
Feb 18 (Reuters) - Moleculin Biotech Inc MBRX.O: MOLECULIN MIRACLE TRIAL DELIVERS 40% PRELIMINARY BLINDED CRC RATE (N=30) MOLECULIN BIOTECH INC - REPORTS 40% PRELIMINARY CRC RATE IN MIRACLE TRIAL MOLECULIN BIOTECH INC - EXPECTS RECRUITMENT OF FIRST 45 SUBJECTS BY Q1 2026 MOLECULIN BIOTECH INC - BLINDED EFFICACY RATES IN MIRACLE TRIAL ENCOURAGING Source text: ID:nGNX4DJ9zs Further company coverage: MBRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Q1 net loss widens as R&D costs rise
Brief: Moleculin Biotech Inc - To Unblind Miracle Trial Data Before June 30, 2026 - SEC Filing
Brief: Moleculin Miracle Trial Delivers 40% Preliminary Blinded CRc Rate (N=30)
U.S. STOCKS ON THE MOVE-Albemarle, Lowe's, nLIGHT
Moleculin Biotech rises as cancer drug shows no heart damage in trials